{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreic3vzw4enjatahysohanmnxaxvq57ubv456rbar42hwl73uxtjioi",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mi76x5ycvmp2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidejr3c2ycqmwdsxof55vsqrnaoztsvfzsg2mtxrclm36cgpnjccm"
    },
    "mimeType": "image/jpeg",
    "size": 447521
  },
  "path": "/news/2026-03-intensive-ldl-lowering-evolocumab-heart.html",
  "publishedAt": "2026-03-29T08:46:02.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Mass General Brigham researchers found that the intensive cholesterol-lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high-risk patients who did not have known atherosclerosis (the build-up of plaque inside artery walls) but did have diabetes. Results were presented at the American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in JAMA.",
  "title": "Intensive LDL lowering with evolocumab reduced first heart attack or stroke in diabetes"
}